866-997-4948(US-Canada Toll Free)

Breast Cancer Diagnostic and Drug Technologies: Global Markets

Published By :

BCC Research

Published Date : May 2018

Category :

In Vitro Diagnostics

No. of Pages : 154 Pages

"Summary

Currently, there are about REDACTED million women living with cancer, globally, and the incidence is gradually increasing. In women, breast cancer is the second leading cause of cancer death. Per World Health Organization (WHO) statistics, about one-third of these cancer fatalities can be decreased through earlier detection and treatment. Early breast cancer treatment and detection have improved the five-year survival rate for women diagnosed with cancer to nearly 80%. The breast cancer diagnostic and drug technology markets include a variety of products approved for breast cancer treatment, including hormonal therapies, chemotherapeutic drugs, combinations and targeted therapies. Many
side effects, adverse reactions and safety concerns have come up associated with newer, innovative drugs. Therefore, drugs with improved safety and efficacy are needed to treat breast cancer effectively.

In countries such as the United States, the chance of a woman developing breast cancer during her lifetime has increased. An estimated 522,000 women died from breast cancer globally in the year 2012. WHO estimates that more than REDACTED million new cancer cases will be diagnosed by 2030. Rising healthcare costs associated with breast cancer treatment, have left several patients either uninsured or with less meaningful coverage than they need and deserve.

With the anticipated increase in the number of breast cancer cases, breast cancer research and development is attractive and requires attention from pharmaceutical firms. Drugs for breast cancer comprise a dynamic and growing global market. The market for breast cancer drugs is predicted to reach REDACTED billion by 2022, with Roche predicted to account for more than half of the market. Common detection techniques for breast cancer are diagnostic mammography and ultrasound followed by biopsy. Studies clearly show that breast cancer treatment is far more effective when cancer is detected at an early stage. Therefore, specific and effective diagnostic tools are needed for early diagnosis.

Reasons for Doing This Study

There has been a significant improvement in understanding the molecular and cellular mechanism of cancer metastasis. As incidence of breast cancer is increasing globally, government agencies and research firms are focused on developing new diagnostics, predictive diagnostics and predictive tools to identify breast cancer in early stages where patient survival is increased. Several targeted therapies have evolved over the last decades and several others are likely to reach the market in the next five years. Due to increased investment, raising cancer awareness and research and development activities the breast cancer diagnostic and therapy market dynamics are expected to change during the forecast
period. The intent of this study is to provide readers with detailed information regarding the latest innovative developments for early identification of breast cancer and targeted therapy. This study looks at different classes of available drug types and their applications. This report also identifies potential pipeline molecules which could translate into clinical practice."

"Report Scope:

This report is an update to Breast Cancer Diagnostics and Therapeutics Market Report-HLC106B.

The objective of the current report is to provide the readers with updated market estimates for the diagnostics and therapeutics market. This report also highlights current and future market potential for breast cancer therapeutics along with a detailed analysis of the competitive environment, pipeline drugs, blockbuster drugs and other diagnostic and therapeutic development.

The report includes breast cancer epidemiology including global and regional prevalence, incidence and mortality rates; regulatory environment for markers and therapeutics along with recent regulatory approvals, current and new technologies, market projections and market share for key market players. Market drivers, trends and potential regional market opportunities for diagnostics and therapeutics are also identified in this report.

The report details currently available diagnostic breast cancer screening tests, breast cancer staging and prognostic technology advancements, predictive diagnostic tests and the latest therapy developments for breast cancer treatment. This study evaluates available tumor marker-based predictive companion tests and FDA approved drugs for treating breast cancer. Screening biomarkers, pipeline analysis, patent analysis and reimbursement scenarios are some additions to the current report.

This report includes market estimates for breast cancer diagnostics (mammography, biopsy and companion diagnostics), therapeutics along with market share of therapeutics by drug class (HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors and hormone receptors), geographic market segmentation of the overall market and global market share by company with special emphasis on developed and underdeveloped geographic regions. For market estimates, data has been provided for the year 2016, as the base year, 2017 and a forecast for 2022.

Report Includes:

- 36 data tables and 47 additional tables
- Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, China, India, Japan, and South Korea
- Estimated revenue of the global mammography, biopsy, companion diagnostic IVD, and therapeutic markets by various segments and subsegments
- Identification of key market dynamics, trends, and opportunities
- Insight into mergers and acquisitions, new product developments, strategies, and research-and-development activities
- Comprehensive profiles of major players in the market, including Abbvie, Inc., Abbott Laboratories, Bristol-Myers Squibb Company, Dako, Eli Lilly and Company, Novartis International AG, and Pfizer, Inc."
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Introduction
Classification of Breast Cancer by Type
Non-invasive Breast Cancers
Ductal Carcinoma Insitu (DCIS)
Lobular Carcinoma Insitu (LCIS)
Invasive Breast Cancers
Invasive (or Infiltrating) Ductal Carcinoma (IDC)
Invasive (or Infiltrating) Lobular Carcinoma (ILC)
Tubular Carcinoma (TC)
Invasive Cribriform Carcinoma
Mucinous Carcinoma
Invasive Papillary Carcinoma
Inflammatory Breast Cancer
Paget's Disease of the Breast
Cytosarcoma Phyllodes
Metastatic Breast Cancer (MBC)
Molecular Subtypes of Breast Cancer
Luminal A
Luminal B Types
HER2 Type
HER2-Amplified
Triple-Negative Breast Cancer (TNBC) or Basal Type
Normal-Like
Causes, Indications and Risk Factors
Symptoms
Breast Cancer Staging
Epidemiology
United States Breast Cancer Incidence
Chapter 4 Breast Cancer Market Dynamics
Market Drivers
Increasing Incidence of Breast Cancer Worldwide
Focused Research and Development for Novel Drugs
High Increase in Healthcare Expenditure and Funding
Increasing Breast Cancer Screening Programs
Favorable Reimbursement for Screening and Diagnosis
Market Restraints
Pricing Pressure Experienced by Innovators
High Cost Associated with New Drug Development and Clinical Trials
Regulatory and Reimbursement Hurdles
Market Opportunity
Rising Female Population in Asia Pacific
Increased Demand for Technology Innovation
Technological Advancement in the Drug Sector
Emergence of Breast Cancer Predictive Tests
Opportunity for Generic Manufacturers to Exploit Patents at the Verge of Expiry
Breast Cancer Therapy: Unmet Needs
Chapter 5 Market Breakdown by Technology
Breast Cancer Diagnostic Market
Mammography
Latest Developments
Mammography Procedure Volumes
Global Mammography Market
Limitations of Mammography
Breast Biopsy Device Market
Introduction
Global Breast Biopsy Device Market
Breast Cancer Predictive Diagnostic Market
Introduction
Predictive Diagnostic Tests
Global Breast Cancer Companion Diagnostic Test Market
Chapter 6 Market Breakdown by Drug Class
Overview
Breast Cancers Drug Classes
Breast Cancer Market
Antimetabolites
Tanaxanes
Aromatase Inhibitors
HER2 Inhibitor
Hormone Therapy
Chapter 7 Market Breakdown by Region
Breast Cancer Incidence by Region
Global Market by Region
North America
Europe
Asia-Pacific
Middle East and Africa (MEA)
South America
Chapter 8 Regulatory Scenario
Breast Cancer Diagnostics and Therapeutics Regulatory Challenges
North America
Food and Drug Administration (FDA)
Europe
Asia-Pacific
Japan
China
South America
Brazil
Chapter 9 Patent Review/New Developments
Patent Review
Companion Diagnostics
Patent Expiration
Chapter 10 Reimbursement Landscape
Introduction
United States
Mammography Procedure Reimbursement
Biopsy Procedure Reimbursement
Breast Cancer Drugs Reimbursement
Germany
Mammography Procedure Reimbursement
Biopsy Procedure Reimbursement
Breast Cancer Drugs Reimbursement
Mexico
Brazil
Chapter 11 Pipeline Analysis
Introduction
Breast Cancer Therapeutics Pipeline by Phases
Phase III
Phase II
Phase I
Breast Cancer Therapeutics Pipeline by Company
AbbVie, Inc.
Array BioPharma, Inc.
AstraZeneca
Belrose Pharmaceuticals
Beta Pharma
BioMarin Pharmaceuticals
CASI Pharmaceuticals, Inc.
Celgene
Celldex Therapeutics
Celsion
Clovis
Clovis Eli Lilly
Novartis
Pfizer
Puma Biotechnology
Roche
Syndax Pharmaceuticals
Tesaro Inc.
Chapter 12 Competitive Landscape
Major Mammography Equipment Market Players
Major Breast Cancer Drug Market Players
Chapter 13 Company Profiles
ABBVIE INC.
Company Overview
Financials
Products
Developments and Strategies
ABBOTT LABORATORIES
Company Overview
Financials
Product Information
Development and Strategies
ASTRAZENECA PLC
Company Overview
Financials
Product Information
Development and Strategy
ATOSSA GENETICS INC.
Overview
Financials
Products
Developments and Strategies
BRISTOL-MYERS SQUIBB COMPANY
Company Overview
Financials
Product Information
Development and Strategies
CCC DIAGNOSTICS LLC
Company Overview
Product Information
DAKO
Company Overview
Product Information
ELI LILLY AND COMPANY
Company Overview
Financials
F. HOFFMANN-LA ROCHE AG
Company Overview
NANOSTRING TECHNOLOGIES
Company Overview
NOVARTIS INTERNATIONAL AG
Company Overview
PFIZER, INC.
Company Overview
Financials
PUMA BIOTECHNOLOGY INC.
Company Overview
Financials
Product Information
Development and Strategies
SANOFI S.A.
Overview
Financials
Development and Strategies
Chapter 14 Abbreviations

List of Table

List of Tables
Summary Table : Global Breast Cancer Diagnostic and Drug Market, by Technology, Through 2022
Table 1 : Difference between Normal and Benign Breast Cancer Cells
Table 2 : New Female Breast Cancer Cases and Deaths in the United States, by Age, 2017
Table 3 : Histological Types, Frequency of Occurrence and Rate of Survival
Table 4 : Different Mucinous Carcinoma
Table 5 : Critical Steps and Genes Involved in Breast Cancer Metastasis
Table 6 : Characteristics of Molecular Subtypes of Invasive Breast Cancer
Table 7 : Local-Regional Recurrence, by Molecular Subtype
Table 8 : Local-Regional Recurrence, by Molecular Subtypes
Table 9 : Local-Regional Recurrence, by Molecular Subtype
Table 10 : Global Breast Cancer Incidence, 2016-2021
Table 11 : Global Breast Cancer Incidence and Mortality, 2008
Table 12 : New Breast Cancer Cases, by Region, 2009 and 2012
Table 13 : New Breast Cancer Cases in the United States, by Gender, 2010-2019
Table 14 : New Female Breast Cancer Cases and Deaths in the United States, by Age, 2011
Table 15 : Breast Cancer Incidence and Mortality in the United States, 2011
Table 16 : Global Breast Cancer Incidence, by Country, Through 2012
Table 17 : Asia-Pacific Breast Cancer Incidence and 40+ Female Population, Through 2017
Table 18 : List of Breast Cancer Drugs and Their Patent Exclusivity Period
Table 19 : Femara Revenue, 2009-2015
Table 20 : Indicative List of Available Generic Versions of Letrazole
Table 21 : Global Mammography Market, by Region, Through 2022
Table 22 : Global Mammography Market, by Device Type, Through 2022
Table 23 : Global Breast Cancer Biopsy Device Market, by Region, Through 2022
Table 24 : Indicative List of Available Breast Cancer Prognostic, Diagnostic, Monitoring and Grading Diagnostics Tests, 2017
Table 25 : Different Classes of Breast Cancer Drugs
Table 26 : Global Breast Cancer Drugs Market, by Drug Class, Through 2022
Table 27 : Global Aromatase Inhibitor Drugs Market, by Drug Type, Through 2022
Table 28 : Global HER2 Inhibitor Drugs Market, by Drug Type, Through 2022
Table 29 : Global Hormone Receptor Drugs Market, by Drug Type, Through 2022
Table 30 : Global Breast Cancer Therapy Market, by Region, Through 2022
Table 31 : North America Breast Cancer Therapy Market, by Country, Through 2022
Table 32 : European Breast Cancer Therapy Market, by Country, Through 2022
Table 33 : Breast Cancer Incidence, Men and Women
Table 34 : Asia-Pacific Breast Cancer Therapy Market, by Country, Through 2022
Table 35 : List of FDA-Approved Drugs, 1996-2017
Table 36 : List of FDA-approved Companion Diagnostics, 2018
Table 37 : List of Breast Cancer Drugs Approved by the EMA, 1995-2018
Table 38 : Companion Diagnostics Patent Review, 2015-2017
Table 39 : Breast Cancer Therapeutics Patent Review, 2010-2018
Table 40 : Patent Expiration of Breast Cancer Drugs
Table 41 : United States Mammography Reimbursement, 2017
Table 42 : United States Biopsy Procedure Reimbursement, 2017
Table 43 : Medicare Part B: Breast Cancer Drugs Payment Limit, 2018
Table 44 : Mammography In-Patient Procedure Reimbursement
Table 45 : In-Patient Biopsy Procedure Codes
Table 46 : Breast Cancer Drugs Gemzar and Herceptin Reimbursement, Germany, 2017
Table 47 : Indicative List of Phase III Breast Cancer Therapy Pipeline
Table 48 : Indicative List of Phase II Breast Cancer Therapy Pipeline
Table 49 : Indicative List of Phase I Breast Cancer Therapy Pipeline
Table 50 : AbbVie, Inc.: Pipeline Drugs
Table 51 : Array BioPharma, Inc.: Pipeline Drugs
Table 52 : AstraZeneca: Pipeline Drugs
Table 53 : Belrose Pharmaceuticals: Pipeline Drugs
Table 54 : Beta Pharma: Pipeline Drugs
Table 55 : BioMarin Pharmaceuticals: Pipeline Drugs
Table 56 : CASI Pharmaceuticals, Inc.: Pipeline Drugs
Table 57 : Celgene: Pipeline Drugs
Table 58 : Celldex Therapeutics: Pipeline Drugs
Table 59 : Celsion: Pipeline Drugs
Table 60 : Clovis: Pipeline Drugs
Table 61 : Eli Lilly: Pipeline Drugs
Table 62 : Novartis: Pipeline Drugs
Table 63 : Pfizer, Inc.: Pipeline Drugs
Table 64 : Puma Biotechnology: Pipeline Drugs
Table 65 : Roche: Pipeline Drugs
Table 66 : Syndax Pharmaceuticals: Pipeline Drugs
Table 67 : Tesaro, Inc.: Pipeline Drugs
Table 68 : AbbVie, Inc.: Company Net Revenue, 2014-2017
Table 69 : Abbott Laboratories: Company Net Revenue, 2014-2017
Table 70 : Abbott Laboratories: Marketed Products, 2016
Table 71 : AstraZeneca Plc.: Company Net Revenue, 2014-2017
Table 72 : AstraZeneca Plc.: Revenue, by Segment, Through 2016
Table 73 : AstraZeneca Plc.: Marketed Products, 2016
Table 74 : Bristol-Myers Squibb Company: Net Revenue, 2014-2016
Table 75 : Eli Lilly and Company: Net Revenue, 2014-2017
Table 76 : Eli Lilly and Company: Net Revenue, by Segment, 2014-2016
Table 77 : Eli Lilly and Company: Revenue, by Oncology Drugs, 2014-2016
Table 78 : F. Hoffmann-La Roche, Ltd.: Net Revenue, by Segment, Through 2017
Table 79 : Novartis International AG: Net Revenue, by Segment, Through 2017
Table 80 : Pfizer, Inc.: Net Revenue, 2014-2016
Table 81 : Pfizer, Inc.: Oncology Drugs Revenue, 2015-2016
Table 82 : Abbreviations Used in Breast Cancer Diagnostic and Drug Technology

List of Chart

List of Figures
Summary Figure : Global Breast Cancer Diagnostic and Drug Market, by Technology, 2016-2022
Figure 1 : Breast Anatomy of Normal and Cancerous Ducts and Lobules
Figure 2 : Market Share of Invasive and Non-invasive Breast Cancer, United States, 2017
Figure 3 : Histopathological Classification of Breast Cancer
Figure 4 : Non-invasive Breast Cancer Cases in the United States, 2015
Figure 5 : New Cases of Invasive Breast Cancer in the United States, 2015
Figure 6 : Invasive Breast Cancers Market Share, by Type
Figure 7 : Occurrence of Molecular Subtypes
Figure 8 : Global Burden of Breast Cancer
Figure 9 : National Cancer Institute Research Funding, 2011-2016
Figure 10 : NCRI Breast Cancer Research Spending, 2010-2017
Figure 11 : Total Number of Mammography Procedures in the United States, Canada and Mexico, 2010-2015
Figure 12 : Total Number of Mammography Procedures in Europe, 2010-2015
Figure 13 : Total Number of Mammography Procedures in Asia-Pacific, 2010-2015
Figure 14 : Global Mammography Market, 2016-2022
Figure 15 : Global Breast Cancer Companion Diagnostic Market, 2016-2022
Figure 16 : Global Breast Cancer Drugs Market Share, by Drug Class, 2016
Figure 17 : Global Aromatase Inhibitor Drugs Market, by Drug Type, 2016-2022
Figure 18 : Global HER2 Inhibitor Drugs Market, by Drug Type, 2016-2022
Figure 19 : Global Hormone Receptor Drugs Market, by Drug Type, 2016-2022
Figure 20 : Global Breast Cancer Incidence, by Region, 2012
Figure 21 : Middle East and Africa Breast Cancer Therapy Market, by Country, 2016-2022
Figure 22 : South America Breast Cancer Therapy Market, by Country, 2016-2022
Figure 23 : Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 24 : Medical Device PMDA Approval Procedure
Figure 25 : Reimbursement of Drugs in Germany
Figure 26 : Global Market Share of Mammography Equipment, by Company, 2016
Figure 27 : Global Market Share of Breast Cancer Drugs, by Company, 2016
Figure 28 : AbbVie, Inc.: Net Revenue, 2013-2016
Figure 29 : AbbVie, Inc.: Lupron Sales, 2014-2016
Figure 30 : Abbott Laboratories: Revenue Share, by Segment, 2016
Figure 31 : AstraZeneca Plc.: Revenue, by Drug, 2014-2016
Figure 32 : Bristol-Myers Squibb Company: Revenue Share, by Region, 2016
Figure 33 : Bristol-Myers Squibb Company: Revenue Share, by Business Segment, 2016
Figure 34 : Eli Lilly and Company: Revenue Share, by Region, 2016
Figure 35 : F. Hoffmann-La Roche, Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 36 : F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, 2014-2017
Figure 37 : F. Hoffmann-La Roche, Ltd.: Breast Cancer Drugs Revenue, by Region, 2016
Figure 38 : Novartis International AG: Breast Cancer Drugs Revenue, 2014-2016
Figure 39 : Pfizer, Inc.: Breast Cancer Drugs Revenue, 2015 and 2016
Figure 40 : Aromasin Revenue, 2010-2013
Figure 41 : Sanofi S.A.: Pharmaceuticals Segment Revenue Share, by Therapy, 2017
Figure 42 : Sanofi S.A.: Breast Cancer Drug Taxotere Revenue, 2011-2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *